Turing, Daraprim, and Refusals to Deal with Generic Manufacturers

Published date19 October 2015
Law FirmPatterson Belknap Webb & Tyler LLP
AuthorWilliam F. Cavanaugh, Jr.,David Kleban
Subject MatterAnti-Competitive,Attorney Generals,Duty to Deal,FTC,Generic Drugs,Monopolization,Mylan Pharmaceuticals,Patent Litigation,Pharmaceutical Distribution,Pharmaceutical Manufacturers,Popular,Retailers,Reverse Payment Settlement Agreements,SCOTUS,Wholesale

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT